HDAC3-IN-2
HDAC3-IN-2 (compound 4i) is a pyrazinyl hydrazide-based HDAC3 inhibitor (IC50: 14 nM) that efficiently targets triple-negative breast cancer cells. HDAC3-IN-2 is cytotoxic with an IC50 of 0.55 μM against 4T1 and an IC50 of 0.74 μM against MDA-MB-231. HDAC3-IN-2 has anti-tumor efficacy in vivo in tumor-bearing mouse models, selectively increasing the acetylation levels of H3K9, H3K27 and H4K12, increasing the contents of apoptosis-related caspase-3, caspase-7 and cytochrome c, and reducing Proliferation-related Bcl-2, CD44, EGFR, and Ki-67 levels[1].
Product Specifications
CAS Number
3033039-28-7
UNSPSC
12352005
Target
Apoptosis; Caspase; DNA/RNA Synthesis; HDAC; Histone Methyltransferase
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hdac3-in-2.html
Purity
99.64
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COC1=CC=C(CNC2=CN=C(C(NNCCC)=O)C=N2)C=C1
Molecular Formula
C16H21N5O2
Molecular Weight
315.37
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Rabbit Polyclonal alpha-1D Adrenergic R/ADRA1D Antibody
TCTA (T-Cell Leukemia Translocation-Altered Gene Protein, T-Cell Leukemia Translocation Altered)
